PharmaDepth

Company profile

BeOne Medicines Ltd.

NASDAQ:ONCBiotechnology: Pharmaceutical Preparations

Drug pipeline (5)

AssetStageRevenueTrialsStatus
Sonrotoclaxapproved—18approved
Zanubrutinibapproved—44approved
Tacabrutidegphase3—4active
PAMIPARIBphase2—2no active trials
LIFIRAFENIBphase1—2no active trials

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (180)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05006716phase1_2recruiting2021-09-132026-11-01BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT06625593phase1recruiting2024-12-092026-12-31BeOne MedicinesA First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT07746141phase1not_yet_recruiting2026-09-042028-09-30BeOne MedicinesA First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
NCT07181681phase1recruiting2025-11-102027-11-01BeOne MedicinesA First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07414836phase1recruiting2026-04-132029-04-30BeOne MedicinesA First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

FDA applications (6)

ApplicationTypeApplicantProducts
BLA 761232BLABeiGene USA, Inc.
BLA 761380BLABEIGENE
BLA 761417BLABEIGENE
NDA 213217NDABEONE MEDICINES USA INC
NDA 218785NDABEONE MEDICINES USA INC